<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04202536</url>
  </required_header>
  <id_info>
    <org_study_id>ID-BVCL-403</org_study_id>
    <nct_id>NCT04202536</nct_id>
  </id_info>
  <brief_title>Switching From Tenofovir Disoproxil Fumarate to Besifovir Dipivoxil Maleate</brief_title>
  <official_title>A Randomized, Open-Label, Parallel, Multi-Center, Non-inferiority, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Switching to Besifovir Dipivoxil Maleate From Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B Patients Who Pretreated With TDF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IlDong Pharmaceutical Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IlDong Pharmaceutical Co Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A research study to observe the safety, efficacy and tolerability of switching from Tenofovir
      Disoproxil Fumarate to Besifovir dipivoxil maleate in patients with chronic hepatitis B
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 29, 2019</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of subjects who maintained hepatitis B virus (HBV) DNA less than 20 IU/mL at the 48th week</measure>
    <time_frame>at the 48th week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of subjects who maintained HBV DNA less than 20 IU/mL at the 24th week</measure>
    <time_frame>at the 24th week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">152</enrollment>
  <condition>Hepatitis B</condition>
  <condition>Besifovir Dipivoxil Maleate</condition>
  <condition>Tenofovir Disoproxil Fumarate</condition>
  <arm_group>
    <arm_group_label>TDF switch to Besifovir Dipivoxil Maleate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tenofovir Disoproxil Fumarate(TDF) 300mg daily switch to Besifovir Dipivoxil Maleate 183mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintaining on TDF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Maintaining on Tenofovir Disoproxil Fumarate(TDF) 300mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Besifovir Dipivoxil Maleate</intervention_name>
    <description>Besifovir 150 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d. Other Name: Besifovir®</description>
    <arm_group_label>TDF switch to Besifovir Dipivoxil Maleate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil fumarate(TDF)</intervention_name>
    <description>300 mg tablet administered orally once daily Other Name: VIREAD®</description>
    <arm_group_label>Maintaining on TDF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 20 years of age and older, Male or female patients

          2. Patients who show positive HBsAg or has a history of chronic hepatitis B for the last
             six months or more before screening

          3. Patients who have been on tenofovir disoproxil fumarate (TDF) monotherapy for more
             than 48 weeks and are taking TDF at the time of clinical screening

          4. At screening, had HBV DNA &lt; 20 IU/mL

          5. Patients who were explained about the purpose, methods and effects of the clinical
             trial and then, signed a written consent form

        Exclusion Criteria:

          1. Patients who have received interferon (including Pegylation formulation) to treat
             chronic hepatitis for more than 12 months.

          2. Patients who have taken Besifovir

          3. Patients who have experienced hepatitis B virus resistance to antiviral drugs

          4. Patient diagnosed with a malignant tumor within 5 years before screening or relapsed
             patient

          5. Patient has history of organ transplantation

          6. Patients who had received the following drugs for the last two months before screening
             (however, short-term use (less than consecutive 14 days) of these drugs and low-dose
             aspirin (100 mg, maximally, 300 mg/day) are allowed.)

               -  Nephrotoxic drugs (e.g. Aminoglycosides, Amphotericin B, NSAIDs)

               -  Hepatotoxic drugs (e.g. Erythromycin, Ketoconazole, Rifampin, Fluconazole,
                  Dapsone)

               -  Anticoagulant (e.g. Warfarin)

          7. Patients who are suspected by an investigator to have the level of immunity decreased
             among patients who had been administered with immunosuppressants within 12 months
             before screening

          8. Patients who had been administered with long-term general corticosteroids (more than
             consecutive 14 days) at a high dose (more than prednisolone 20 mg daily*) within three
             months before screening (In case of local corticosteroids, an investigator decides
             it.)

               -  It is equal to cortisone 125 mg, hydrocortisone 100 mg, prednisone 20 mg,
                  methylprednisolone 16 mg, triamcinolone 16 mg, dexamethasone 3 mg, betamethasone
                  2.4 mg

          9. Patients who have a past medical history of clinical alcohol or drug abuse within a
             year before screening or now are abusers

         10. Patients with hepatitis C virus, hepatitis D virus or human immunodeficiency virus

         11. Patients who have other hepatic diseases (hematochromatosis, Wilson's disease,
             alcoholic liver diseases, nonalcoholic steatohepatitis, α1-antitrypsin deficiency)
             except hepatitis B

         12. Patient concerned about the decline in daily activity or not able to understand the
             objectives and methods due to the psychiatric problems

         13. Patients who showed Glomerular Filtration Rate (GFR) less than 50 mL/min by
             calculating Modification of Diet in Renal Disease (MDRD: 1.86 x phosphocreatine -1.154
             x age -0.203 (x 0.742 for women)) during screening

         14. Patients who showed alpha-fetoprotein(AFP) more than 50 ng/mL during screening and are
             estimated to have hepatocellular carcinoma (HCC) through liver/abdomen CT scans

         15. At least one of the following laboratory values during screening

               -  Hemoglobin &lt; 9.0 g/dL

               -  Absolute neutrophil count (ANC) &lt; 1.0 x 10^9 /L (1000 /mm^3)

               -  Platelet count &lt; 75 x 10^9 /L (100 x 10^3 /mm3)

               -  Serum creatinine &gt; 1.5 mg/dL

               -  Serum amylase &gt; 2 x upper limit normal (ULN) and Lipase &gt; 2 x ULN

               -  Total Bilirubin &gt; 2 x ULN

               -  Serum albumin &lt; 28 g/L (2.8 g/dL)

         16. Pregnant women, lactating women, or patients who planned pregnancy during a trial
             period

         17. Patients who participate in other clinical trials or is supposed to do so during the
             study period

         18. Patients who have hypersensitivity to the clinical trial drug in this clinical trial

         19. Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency
             or glucose-galactose malabsorption

         20. Patients who are considered to be unacceptable in this study under the opinion of the
             investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yoan Park</last_name>
    <phone>82-2-526-3524</phone>
    <email>yapark@ildong.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hyoju Pyo</last_name>
    <phone>82-2-526-3192</phone>
    <email>hyoju@ildong.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Korea University Medical Center</name>
      <address>
        <city>Ansan</city>
        <state>Kyounggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyung Joon Yim, M.D., Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Hyung Joon Yim, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 16, 2019</study_first_submitted>
  <study_first_submitted_qc>December 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2019</study_first_posted>
  <last_update_submitted>December 16, 2019</last_update_submitted>
  <last_update_submitted_qc>December 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

